Sorrento Therapeutics (NSDQ:SRNE) subsidiary Scilex Pharmaceuticals said today that it filed a marketing authorization application seeking approval for its ZTlido lidocaine patch.
The San Diego, Calif.-based company said it is pursuing a hybrid regulatory pathway with the Medicines and Healthcare Products Regulatory Agency in the U.K., which will serve as the lead review agency. The company also plans to file for review in other countries, including Germany, France, Spain, Italy and Ireland.
Get the full story at our sister site, Drug Delivery Business News.
The post Scilex seeks EU nod for ZTlido lidocaine patch appeared first on MassDevice.
from MassDevice http://ift.tt/2igCvm6
Cap comentari:
Publica un comentari a l'entrada